Clinical Trial

CtDNA-guided Maintenance Therapy in Pancreatic Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to conduct a large-scale prospective clinical trial to evaluate the efficacy and safety of capecitabine monotherapy as maintenance treatment following standard adjuvant chemotherapy (gemcitabine plus capecitabine) in patients with resectable pancreatic cancer, and to analyze whether ctDNA-MRD testing can guide the selection of postoperative maintenance therapy.
Trial Details
NCT Number NCT07054879
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Pancreatic Cancer
Enrollment 70 participants
Start Date 2024-11-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-08